Latest Articles
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses Nature.com
Published: April 23, 2024, 7 a.m.
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers - Cancer Therapy Advisor
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers Cancer Therapy Advisor
Published: March 17, 2024, 7 a.m.
Gynecologic cancers: Early detection and understanding symptoms can save lives - University of Alabama at Birmingham
Gynecologic cancers: Early detection and understanding symptoms can save lives University of Alabama at Birmingham
Published: Jan. 26, 2024, 8 a.m.
Link copied to clipboard!